The Efficacy of CAPCT in Patients With PTCL

Inclusion Criteria: * 1\. Patients with histopathologically confirmed peripheral T-cell lymphoma (PTCL), with exclusion of NK/T-cell lymphoma. * 2\. Patients who are treatment-naïve or have relapsed/refractory disease. * 3\. Patients who are intolerant to standard chemotherapy regimens for various reasons, including those aged ≥75 years, or those aged \<75 years but deemed by the investigator to be unsuitable for or unable to tolerate chemotherapy. * 4\. Patients aged ≥18 years, male or female. * 5\. Eastern Cooperative Oncology Group (ECOG) performance status score of 0-3. * 6\. Absolute neutrophil count ≥1.5×10⁹/L, platelet count ≥50×10⁹/L, and hemoglobin ≥70 g/L. * 7\. Estimated life expectancy ≥3 months. * 8\. Voluntary signing of written informed consent. Exclusion Criteria: * 1\. Pregnant or lactating women, or fertile patients of childbearing potential who are unwilling to adopt contraceptive measures. * 2\. Patients with chronic heart failure of New York Heart Association (NYHA) functional class III or IV; or those with a history of any of the following cardiac conditions within 6 months: acute coronary syndrome; acute heart failure (NYHA functional class III or IV); or significant ventricular arrhythmias (sustained ventricular tachycardia, ventricular fibrillation, or sudden cardiac death after resuscitation). * 3\. Hepatic dysfunction (total bilirubin \>1.5× the upper limit of normal \[ULN\]; alanine aminotransferase \[ALT\] and aspartate aminotransferase \[AST\] \>2.0× ULN, or \>5× ULN in patients with hepatic involvement); or renal dysfunction (serum creatinine \>1.5× ULN). * 4\. Confirmed central nervous system (CNS) involvement by lymphoma. * 5\. Receipt of prior myelosuppressive symptomatic treatment within 7 days before enrollment. * 6\. Active hemorrhage/bleeding. * 7\. Patients with acquired immunodeficiency syndrome (AIDS), syphilis, or active hepatitis B (HBV DNA \>1×10⁵ copies/mL) or hepatitis C. * 8\. Receipt of grade II or higher surgery within 3 weeks prior to treatment. * 9\. Psychiatric disorders or inability to provide informed consent. * 10\. Patients deemed by the investigator to be unsuitable for participation in this trial. * 11\. Known allergy to any component of the investigational drug.